News
Discover more about Annogen and how we support the identification of regulatory DNA elements and non-coding genetic variants to help improve patient, plant, and aninmal health.
NEWS
PRESS RELEASE - April 2022 Annogen signs another collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA using SuRE™ screening technology.
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
NEWS
Novel approach could aid selective breeding in cattle
Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical traits, such as productivity or disease tolerance, in livestock.
The study, involving Roslin researchers and their commercial partner Annogen, will focus on identifying sites in cattle DNA linked to important genes for livestock production and welfare.
NEWS
NEWS – Annogen Featured in C2W
Many diseases are determined by differences in as yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome.
Read this article by Marysa van den Berg on the C2W website.
VACANCY
VACANCY – Part-Time Position Office Manager
We are looking for an energetic and motivated office manager for our growing company. Tasks will be focused on professionalization of our organization including HR, administration, logistics etc. We are looking for someone that can identify tasks him/herself and that enjoys taking the initiative. The job will be for 12-20 hours per week, ideally 3 or 5 half days but this is flexible and can be discussed.
NEWS
PRESS RELEASE – Amsterdam, 30 November 2021 Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company.
Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants.
NEWS
Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
NEWS
Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression
Annogen and KeyGene the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate in identifying non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
NEWS
Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.
Sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and consequently, Annogen was incorporated with exclusive rights to commercialize the technology outside the gene therapy field.
CBO APPOINTED
February 1, 2020 - Annogen appoints Victor Schut as Chief Business Officer
After supporting sister company Gen-X as CBO in 2019 and following the recent execution of its exclusive deal with Dutch gene therapy company uniQure he will now focus on setting up the spin-off business around the SuRE technology outside the gene therapy field.